Licensing, Long-Term Care Facilities, Nurses and Virus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Licensing

Long-Term Care Facilities

Nurses

Virus

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. It is a virus-based therapeutic vaccine that encodes neoantigens picked by NEC’s Neoantigen Prediction System.

Long-Term Care Facilities

Long-Term Care Facilities Trials Virus Clinical Trials

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Hospitals

Hospitals Treatment Long-Term Care Facilities Trials

Drug Discovery Digest

Clinical Catch-Up: January 18-22 | BioSpace

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Stay Connected